SCHEMBL4394971

SCHEMBL4394971

CC(C)(C)NC(=O)N(Cc1ccc(C(=O)OCc2ccccc2)cc1)C(C)(C)CCN

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 2/20 0.46
KMT2A Q03164 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
RAB9A P51151 3/20 0.44
GAA P10253 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.41
TSHR P16473 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4394968 0.80 ALDH1A1 (0.46) MAPTALDH1A1HPGDLMNAKMT2A
SCHEMBL27518717 0.77 MAPT (0.52) MAPTALDH1A1HPGDLMNAKMT2A
SCHEMBL2477195 0.76 ALDH1A1 (0.49) MAPTALDH1A1HPGDLMNAKMT2A
SCHEMBL9837067 0.72 ALDH1A1 (0.70) MAPTALDH1A1HPGDLMNAKMT2A
SCHEMBL13575261 0.72 MEN1 (0.58) MAPTALDH1A1LMNAKMT2ATDP1
SCHEMBL9222805 0.71 KMT2A (0.69) MAPTALDH1A1HPGDLMNAKMT2A
SCHEMBL14487915 0.70 KMT2A (0.73) MAPTALDH1A1HPGDLMNAKMT2A
SCHEMBL312287 0.70 KMT2A (0.92) MAPTALDH1A1HPGDLMNAKMT2A
SCHEMBL18650047 0.69 ALDH1A1 (0.53) MAPTALDH1A1HPGDLMNAKMT2A
Hydrochloric Acid SCHEMBL4371608 0.69 KMT2A (0.71) MAPTALDH1A1HPGDLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 MAPT 1576/4885ALDH1A1 1040/4885HPGD 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.